TIL抗肿瘤免疫疗法的临床疗效观察

CLINICAL USE OF TLL IN ADOPTIVE IMMUNOTHERAPY FOR ADVANCED CANCERS

以ＩＬ－２激活的肿瘤浸润性淋巴细胞（ｔｕｍｏｒ ｉｎｆｉｌｔｒａｔｉｎｇ ｌｙｍｐｈｏｃｙｔｅ，ＴＩＬ），治疗多种晚期恶性肿瘤共１６例。结果表明，多数患者自觉症状有改善，生活质量提高，部分患者的癌性症状改善明显，１６例患者中，ＰＲ９例（３７．５％），ＮＣ７例（４３．７％），ＰＤ３例（１８．７５％）。ＴＩＬ作为一种新的生物治疗方法，其临床抗肿瘤疗效是肯定的，具有一定的临床应用价值。

Sixteen patients with advanced cancers were treated with expanded tumor-infiltrating lympocytes (TIL) and conjunct use of recombinant interleukin-2 (riL-2)im. The TIL were first separated from the fresh tumor tissue of the patient and then cultured in the presence of rIL-2 (1000 units/ml)for 2-3 weeks. the expanded TIL suspended in NS,1.2-3.8×109 cells in one dose,were transfused back to the patient iv qd for 3 days. Concurrently,rIL-2 100 000 U im qd was given for 10 days. Each course of treatment lasted for 10 days,The results of treatment,as monitored by B ultrasonography,CT scan and immnnological examinations,revealed PR in 6 cases,NC in 7 and PD in 3.On follow-up,13 of the l6 patients survived more than 6 months and one of them had been alive and about for 460 days,The side effects of the therapy were mild,with transient fever of about 38℃ and general malaise lasting for 24 hours at most.